Key result
GLP-1 and GIP analogues reduce systolic blood pressure by up to ~7 mmHg.
Why the study?
Potent analogues of GLP-1 and GIP reduce systolic blood pressure and have substantial cardiovascular protective effects, but their mechanisms and potential antihypertensive use in overweight or obese patients require clarification.
Do GLP-1 and GIP analogues reduce blood pressure in overweight or obese patients?
Do GLP-1 and GIP analogues reduce blood pressure in overweight or obese patients?
GLP-1 and GIP analogues can reduce systolic blood pressure by up to 7.2 mmHg, highlighting their potential future role as antihypertensive agents in overweight or obese patients.
Supports BP reduction as contributor to CV protection with GLP-1/GIP analogues; leaves open weight-independent mechanisms.
Potent analogues of GLP-1 and GIP are used in the indication of weight reduction. In addition to their significant effects on body weight., these agents reduce systolic blood pressure up to 7,2mmHg. The reduction in blood pressure partly explains the substantial cardiovascular protective effect observed with these molecules. The underlying mechanisms are multifactorial, involving weight-related, vascular, neurogenic, renal, and anti-inflammatory pathways. The desired effect on weight leads to improved treatment adherence compared with other anti-hypertensive therapeutic modalities. Consequently GLP-1 and GIP analogues could potentially be used for antihypertensive indications in the future for overweight or obese patients.
No takes yet. Share an insight, caveat, or question.
Oweini et al. (2026) conducted a review in Overweight or obesity. GLP-1 and GIP analogues was evaluated on Systolic blood pressure. Potent GLP-1 and GIP analogues reduce systolic blood pressure by up to 7.2 mmHg, which partly explains their cardiovascular protective effects in overweight or obese patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: